|
Multiple Sclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
These data support a link between MS and EBV through antibodies that cross-react between EBV proteins and the MBP autoantigen.
|
31515129 |
2020 |
|
Multiple Sclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Multiple sclerosis (MS) is correlated with increased deimination of myelin basic protein (MBP) in the central nervous system.
|
31805269 |
2020 |
|
Multiple Sclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The H. perforatum and O. biennis extracts ameliorated the increased brain tissue MOG and MBP values for animals with MS. H. perforatum and O. biennis extract decreased the TOS and OSI values for brain tissue and increased TAS levels in brain tissue of animals with MS.
|
30957550 |
2019 |
|
Multiple Sclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Myelin basic protein (MBP) plays an important role in the pathogenesis of multiple sclerosis.
|
30496641 |
2019 |
|
Multiple Sclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Glatiramer acetate (GA) is the most commonly used drug for Multiple sclerosis (MS) patients that exerts an immunomodulatory effect against Myelin basic protein (MBP) antigen.
|
31038378 |
2019 |
|
Multiple Sclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Bioenergetics, oxygen and ion metabolism dominate the metabolic and biochemical pathways that maintain neuronal viability and impulse transmission which directly or indirectly point to mitochondrial integrity and adenosine triphosphate (ATP) availability indicating the involvement of mitochondria in the pathogenesis of MS. Loss of myelin proteins including myelin basic protein (MBP), proteolipid protein (PLP), myelin associated glycoprotein (MAG), myelin oligodendrocyte glycoproetin (MOG), 2, 3,-cyclic nucleotide phosphodiestarase (CNPase); microglia and microphage activation, oligodendrocyte apoptosis as well as expression of inducible nitric oxide synthase (i-NOS) and myeloperoxidase activities have been implicated in a subset of Balo's type and relapsing remitting MS (RRMS) lesions indicating the involvement of metabolic defects and oxidative stress in MS.
|
29246870 |
2019 |
|
Multiple Sclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
We analyzed by flow cytometry CEACAM-1 expression on myelin basic protein (MBP)-stimulated CD4<sup>+</sup> and CD8<sup>+</sup> T lymphocytes of 56 MS patients with a diagnosis of either PPMS (<i>n</i> = 16), relapsing-remitting MS (<i>n</i> = 20), or benign MS (<i>n</i> = 20) and 40 age- and sex-matched healthy controls.
|
31142599 |
2019 |
|
Multiple Sclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, we demonstrate that overexpression of the transcription factor SOX10 is sufficient to generate surface antigen O4-positive (O4<sup>+</sup>) and myelin basic protein-positive OLs from hPSCs in only 22 days, including from patients with multiple sclerosis or amyotrophic lateral sclerosis.
|
29337119 |
2018 |
|
Multiple Sclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The sera of 34 NMOSD patients showed elevated levels of antibodies against MAP and MBP compared to healthy controls (44% vs. 5%, p < 0.0002 and 50% vs. 2%, p < 0.0001, respectively), while, unlike in MS, responsiveness to EBV was similar.
|
29519720 |
2018 |
|
Multiple Sclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Together with cognate MOG-specific T cells, these Abs enhanced T-cell infiltration; together with myelin basic protein-specific T cells, they induced demyelination associated with deposition of C9neo, resembling a multiple sclerosis type II pathology.
|
30014603 |
2018 |
|
Multiple Sclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
We quantify changes in lysine and arginine PTMs on MBP derived from mice induced with an experimental autoimmune encephalomyelitis (EAE) model of MS using liquid chromatography tandem mass spectrometry.
|
29111742 |
2018 |
|
Multiple Sclerosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In the authors' opinion, this may be mediated by cross-reactivity of B cell receptors for GA with antigen (possibly myelin basic protein) expressed in the MS lesion.
|
30315499 |
2018 |
|
Multiple Sclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
We used myelin basic protein (MBP)-proteolipid protein (PLP)-induced experimental autoimmune encephalomyelitis (EAE) in C57BL/6 (B6) mice as B cell-dependent model of MS. Mice were treated intraperitoneally either at the peak of EAE or at 60 days after onset with 200 μg murine anti-CD52 vs. IgG2a isotype control antibody for five consecutive days.
|
30098594 |
2018 |
|
Multiple Sclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
No significant difference in the frequency of anti-MBP<sub>85⁻98</sub> antibodies was found between patients with MS and those with NMOSD.
|
30544526 |
2018 |
|
Multiple Sclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Increased lectin binding was not observed for anti-myelin basic protein (one of the major autoAb in MS) Ab compared to total serum Ab.
|
30369266 |
2018 |
|
Multiple Sclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Further, the antibody-mediated cleavage of encephalitogenic MBP peptide 81-103, flanked by two fluorescent proteins, can serve as a novel biomarker for MS.
|
30139963 |
2018 |
|
Multiple Sclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
We measured CSF cell counts; concentrations of proteins, glucose, interleukin (IL)-6, IL-10, soluble IL-2 receptor (sIL-2R), and myelin basic protein; and IgG index in patients with multiple sclerosis (MS, n = 64), neuromyelitis optica spectrum disorder (NMOSD, n = 35), tumefactive demyelinating lesion (TDL, n = 17), CNS lymphoma ( n = 12), or glioma ( n = 10).
|
28657431 |
2018 |
|
Multiple Sclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Importantly for the potential causation of MS, MBP from MS patients breaks down differently from the MBP in aged controls.
|
30223497 |
2018 |
|
Multiple Sclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Myelin basic protein (MBP) is a major target of T cells in lesions of multiple sclerosis (MS) patients and its animal model, experimental autoimmune encephalomyelitis (EAE).
|
28889362 |
2018 |
|
Multiple Sclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The Lys<sup>91</sup> and Pro<sup>96</sup> of MBP<sub>87-99</sub> are crucial T-cell receptor (TCR) anchors and participate in the formation of trimolecular complex between the TCR-antigen (peptide)-MHC (major histocompability complex) for the stimulation of encephalitogenic T cells that are necessary for EAE induction and are implicated in MS.
|
29385090 |
2018 |
|
Multiple Sclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
We review the experimental approaches of tolerance-inducing vaccination in relapsing and progressive forms of MS that have reached the clinical development phase, including vaccination with autologous T cells, autologous tolerogenic dendritic cells, T cell receptor peptide vaccination, altered peptide ligand, ATX-MS-1467, cluster of differentiation (CD)-206-targeted liposomal myelin basic protein peptides and DNA vaccination.
|
29761344 |
2018 |
|
Multiple Sclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Acutely demyelinating white matter lesions from MS autopsy tissue were stained with the lipid dye oil red O. Myelin basic protein (MBP), a major membrane protein of myelin, was digested with trypsin.
|
29517817 |
2018 |
|
Multiple Sclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
MBP is an abundant myelin protein involved in demyelinating diseases, such as multiple sclerosis.
|
28694532 |
2017 |
|
Multiple Sclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
For this classification of MS lesions, identification of myelin with histological stains [such as luxol fast blue-PAS] or by immunohistochemistry using antibodies against myelin basic-protein (MBP) or proteolipid-protein (PLP), as well as, detection of macrophages/microglia by, e.g., anti-CD68 is sufficient.
|
27988845 |
2017 |
|
Multiple Sclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study was aimed at the development of an immunosensor for the simultaneous quantification of Myelin Basic Protein (MBP) and Tau proteins in cerebrospinal fluid (CSF) and serum, obtained from Multiple Sclerosis (MS) patients.
|
27816592 |
2017 |